Vaxart, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vaxart, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $45.00K, a 15.09% decline year-over-year.
- Vaxart, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $53.00K.
- Vaxart, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $1.43M, a 44.15% increase year-over-year.
- Vaxart, Inc. stock issued during period, value, new issues for the quarter ending 2022-12-31 was $8.59M.
- Vaxart, Inc. stock issued during period, value, new issues for fiscal 2022 was $17.24M, a 85.90% decline from fiscal 2021.
- Vaxart, Inc. stock issued during period, value, new issues for fiscal 2021 was $122.21M.
- Vaxart, Inc. stock issued during period, value, new issues for fiscal 2019 was $2.44M.
- Vaxart, Inc. stock issued during period, value, new issues for fiscal 2017 was $0.00.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $45.00K 10-Q · filed 2026-08-06 | |
| 2025-06-30 | $53.00K 10-Q · filed 2026-08-06 | |
| 2023-03-31 | $1.43M 10-Q · filed 2023-05-04 | $17.68M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | $8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $17.24M 10-K · filed 2023-03-15 |
| 2022-09-30 | $4.85M 10-Q · filed 2022-11-09 | $8.65M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-06-30 | $2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $24.09M derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-03-31 | $992.00K 10-Q · filed 2023-05-04 | $57.49M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $122.21M 10-K · filed 2023-03-15 |
| 2021-09-30 | $20.30M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $36.20M 10-Q · filed 2022-08-08 | |
| 2020-09-30 | $97.03M 10-Q · filed 2020-11-12 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.44M 10-K · filed 2022-02-24 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | |
| 2019-06-30 | $7.74M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $2.44M 10-Q · filed 2019-08-08 | |
| 2017-06-30 | $0.00 10-K · filed 2017-09-01 | |
| 2015-06-30 | $7.50M 10-K · filed 2016-09-13 | |
| 2014-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-13 | $26.80M 10-K · filed 2016-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |